Glaukos is a medical devices business based in the US. Glaukos shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $86.86 – a decrease of 7.43% over the previous week. Glaukos employs 995 staff and has a trailing 12-month revenue of around $404.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $86.86 |
|---|---|
| 52-week range | $77.10 - $163.71 |
| 50-day moving average | $99.77 |
| 200-day moving average | $127.70 |
| Wall St. target price | $125.38 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $87.61 from 2025-05-02
| 1 week (2025-04-29) | -6.63% |
|---|---|
| 1 month (2025-04-07) | 1.79% |
| 3 months (2025-02-07) | -42.77% |
| 6 months (2024-11-07) | -37.12% |
| 1 year (2024-05-07) | -18.86% |
|---|---|
| 2 years (2023-05-05) | 60.78% |
| 3 years (2022-05-06) | 111.87% |
| 5 years (2020-05-06) | 115.21% |
Valuing Glaukos stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Glaukos's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $404.5 million |
|---|---|
| Gross profit TTM | $306.4 million |
| Return on assets TTM | -6.68% |
| Return on equity TTM | -20.36% |
| Profit margin | -30.57% |
| Book value | $13.46 |
| Market Capitalization | $5 billion |
TTM: trailing 12 months
We're not expecting Glaukos to pay a dividend over the next 12 months.
Over the last 12 months, Glaukos's shares have ranged in value from as little as $77.102 up to $163.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos's is 0.88. This would suggest that Glaukos's shares are less volatile than average (for this exchange).
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .